The CPG and Therapeutic Guidelines provide evidence-based recommendations for the use of cholinesterase inhibitors (donepezil, rivastigmine and galantamine), along with the N-methyl-D-aspartate receptor antagonist (memantine) in AD. The gene discussed is BCHE; the disease is Alzheimer disease.